# SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

DUBLIN, Calif., December 17 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that investigators have dosed the first patient in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib. The trial is expected to enroll up to 105 patients at five study centers.

The Phase 1b trial is an open label, dose-escalation study designed to assess the safety and tolerability of MP470 in combination with these standard of care chemotherapy regimens, and to define the dose of MP470 to advance into Phase 2 combination studies. Additionally, the Company will assess pharmacokinetic and biomarker data from the study. The trial is open to chemotherapy naïve or treatment experienced patients with a variety of solid tumors irrespective of previous lines of therapy.

"MP470 shows significant preclinical synergy with all of these well established chemotherapy agents. Its preclinical toxicology profile, as well as preliminary safety data from our ongoing Phase 1 trial suggests it will be safe to combine it with these regimens," said Dr. Gregory Berk, Chief Medical Officer of SuperGen. "In preclinical models, MP470 also suppresses Rad51, a protein that plays a key role in the mechanism of resistance to these treatments. We believe this offers the potential for MP470 to improve on the efficacy of these therapies. The multi-arm, Phase 1b design allows us to accelerate the clinical development of MP470 which will expedite the timeline to our Phase 2 program."

About MP470

MP470 is an oral, multi-targeted tyrosine kinase inhibitor that inhibits the mutant forms of c-KIT, PDGFR and FLT3, and suppresses c-MET and c-RET. MP470 also suppresses the Rad51 protein, a critical component of double- stranded DNA repair in cancer cells. Preclinical testing of MP470 has identified anti-tumor activity against a wide spectrum of cancers and is synergistic with a variety of chemotherapy agents as well as radiation therapy. MP470 is currently being evaluated in a single agent Phase 1 trial in patients with solid tumors.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors, and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding the ability of our products to enter clinical trials and the potential validation of our discovery process to produce new compounds. SuperGen's products may not enter clinical trials, and even if these products do enter clinical testing, there is no assurance that these tests will be successful. Additionally, the early successes in preclinical work may not be a validation of our discovery process and past success may not predict future success. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward- looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward- looking statements, whether as a result of new information, future events or otherwise.

Contacts:
SuperGen
Timothy L. Enns
S.V.P., Corporate Communications& Business Development

(925) 560-0100
tenns@supergen.com

SuperGen
Mary M. Vegh
Manager, Investor Relations
(925) 560-2845
mary.vegh@supergen.com

SOURCE SuperGen, Inc.

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications& Business Development, +1-925-560-0100, tenns@supergen.com, or Mary M. Vegh, Manager, Investor Relations, +1-925-560-2845, mary.vegh@supergen.com, both of SuperGen, Inc.
Web site: http://www.supergen.com
08:00 EST http://www.prnewswire.com